ArticleiScience2026
Amelioration of neurogenic erectile dysfunction by ST36 electroacupuncture.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cavernous nerve (CN) injury-induced neurogenic erectile dysfunction (ED) remains clinically intractable, mainly driven by post-injury cavernous autonomic imbalance and subsequent pathological remodeling. In a bilateral cavernous nerve injury (BCNI) rat model, we detected early sustained sympathetic hyperactivity and parasympathetic suppression in the corpus cavernosum, which significantly correlated with fibrotic progression. Electroacupuncture (EA) at Zusanli (ST36), a non-invasive neuromodulation, effectively reversed this autonomic imbalance, achieving significant erectile function recovery and attenuated penile pathological remodeling. Proteomics showed that EA-ST36 markedly upregulated cavernous L-arginine biosynthesis, with key enzyme argininosuccinate synthase 1 (ASS1) enriched in cavernous endothelial cells. α-Methyl-DL-aspartate (α-MDLA) inhibition of this pathway abolished EA's protective effects, which were rescued by arginine supplementation, confirming that EA acts via the L-arginine/nitric oxide (NO) signaling. Collectively, non-invasive ST36 EA is a promising strategy for penile rehabilitation in neurogenic ED patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.